APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.

George K K LauMing-Lung YuGrace WongAlexander ThompsonHasmik GhazinianJin-Lin HouTeerha PiratvisuthJi-Dong JiaMasashi MizokamiGregory ChengGuo-Feng ChenZhen-Wen LiuOidov BaatarkhuuAnn Lii ChengWoon Leung NgPatrick LauTony MokJer-Ming ChangSaeed HamidA Kadir DokmeciRino A GaniDiana A PayawalPierce ChowJoong-Won ParkSimone I StrasserRosmawaiti MohamedKhin Maung WinTanwandee TawesakShiv Kumar SarinMasao Omata

Published in: Hepatology international (2021)

We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

Keyphrases

liver failure
hepatitis b virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
drug induced
peritoneal dialysis
stem cells
molecular docking
patient reported